Advanced Search


Study ID Status Title Patient Level Data
SB681323/011 Completed A study to investigate the excretion balance of SB-681323 in healthy male volunteers [Type 3C]
SB-705498/008 Completed A single blind, placebo controlled, multi-centre study to investigate the pharmacokinetics, safety, tolerability and pharmacodynamics of the TRPV1 antagonist SB-705498 against the pain of acute migraine.
SB-714703/003 Completed An open, randomised, multi-centre dose ranging phase II study to evaluate LAPDAP in combination with three different doses of artesunate Study Listed on
SCA100223 Completed A Multicenter, Double-Blind, Placebo-Controlled, Fixed-Dose, 8-Week Evaluation of the Efficacy and Safety of Lamotrigine in the Treatment of Depression in Patients with Type II Bipolar Disorder Study Listed on
SCA102833 Completed The Evaluation of Lamictal as an Add-on Treatment for Bipolar I Disorder in Children and Adolescents, 10 to 17 Years of Age Study Listed on
SCA104753 Completed An Open-Label Extension Study to Assess the Safety of Lamotrigine in Subjects with Bipolar Disorder, who are in remission following a manic/hypomanic index episode or a depressive index episode.
SCA104779 Completed Study SCA104779, an evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar I disorder patients Study Listed on
SCA106052 Completed Study SCA106052, a clinical evaluation of BW430C (lamotrigine) in bipolar I disorder– Long-term extension study (extension of study SCA104779 (NCT00550407)) Study Listed on
SCA30905 Completed A mulitcentre, double-blind, randomised, fixed-dose evaluation of the safety and efficacy of Lamictal (lamotrigine) compared to placebo as an add-on therapy to lithium or another mood stabiliser in the treatment of bipolar depression, followed by long-term prevention of relapse and recurrence of depression and/or mania in patients with bipolar disorder
SCA30924 Completed Double blind placebo controlled study of lamictal in acute bipolar depression Study Listed on
SCA30926 Completed A Multi-Center, Double blind, Placebo-controlled, Randomized, Parallel Group Evaluation of the Efficacy of a Flexible Dose of Lamotrigine versus Placebo As Add-On Therapy In Schizophrenia Study Listed on
SCA40917 Completed Lamictal for use in treatment of Bipolar Disorder In Adults. A Practical Clinical Assessment of Tolerability and Clinical Effectiveness. Study Listed on
SCB107718 Completed Double blind, randomised, placebo controlled study to evaluate the safety, tolerability and pharmacokinetics of single doses of GSK1014802 and the effect of single doses of GSK1014802 or lamotrigine on resting motor threshold in healthy volunteers
SCO100250 Completed A Randomized, Double-Blind, Parallel Group, 52-Week Study to Compare the Effect of Fluticasone Propionate/Salmeterol Diskus Combination Product 250/50mcg BID with Salmeterol Diskus 50mcg BID on the Annual Rate of Moderate/Severe Exacerbations in Subjects with Chronic Obstructive Pulmonary Disease Study Listed on
SCO100646 Completed Clinical Evaluation of GW815SF for COPD -Assessment of the Effect of Addition of Fluticasone Propionate to Salmeterol Xinafoate 50 after Switching under Double-blinded conditions to GW815SF50/250 in COPD
SCO100648 Completed Clinical Evaluation of GW815SF for Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)“ A Long-term Treatment Study of GW815SF50/500µg in Chronic Obstructive Pulmonary Disease -
SCO104925 Completed A randomized, double-blind placebo-controlled study of treatments with salmeterol, fluticasone propionate and their combination to evaluate novel endpoints in patients with chronic obstructive pulmonary disease Study Listed on
SCO104960 Completed A multicentre 3 year longitudinal prospective study to identify novel endpoints and compare these with forced expiratory volume in 1 second (FEV1) for their ability to measure and predict COPD severity and its progression over time
SCO104962 Completed A randomised, double-blind, double dummy, 3 way crossover study evaluating the effects of a combination of Seretide 50/500mcg twice daily plus tiotropium bromide 18mcg once daily compared with the individual agents (tiotropium bromide 18mcg alone and Seretide50/500mcg alone) in the treatment of subjects with COPD Study Listed on
SCO105782 Withdrawn A randomized, double-blind, parallel-group study of fluticasone propionate/salmeterol combination (FSC 250/50mcg) twice daily and salmeterol (SAL 50mcg) twice daily to validate a new shortness of breath questionnaire in patients with chronic obstructive pulmonary disease (COPD)
SCO107227 Completed A 12 month open-label randomized parallel group study to investigate the influence of salmeterol xinafoate/fluticasone propionate either in fixed combination or separately via Diskus inhalers on the course of the disease and frequency of exacerbations in subjects with severe and very severe COPD.
SCO30003 Completed A multicentre, randomised, double-blind, parallel group, placebo-controlled study to investigate the long-term effects of salmeterol/fluticasone propionate (Seretide tm) 50/500mcg BD, salmeterol 50mcg BD and fluticasone propionate 500mcg BD, all delivered via the Diskus tm/Accuhaler tm inhaler, on mortality and morbidity of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment Study Listed on
SCO30005 Completed A 13-week, double-blind, parallel group, multi-centre study to compare the bronchial anti-inflammatory activity of the combination of salmeterol/fluticasone propionate 50/500mcg twice daily compared with placebo twice daily in patients with Chronic Obstructive Pulmonary Disease (COPD) Study Listed on
SCO40036 Completed Multicentre, Randomised, Double-Blind, Double Dummy, Parallel Group, 104-week Study to Compare the Effect of the Salmeterol/Fluticasone Propionate Combination Product (SERETIDE*) 50/500mcg Delivered Twice Daily via the DISKUS*/ACCUHALER* Inhaler with Tiotropium Bromide 18 mcg Delivered Once Daily via the HandiHaler Inhalation Device on the Rate of Health Care Utilisation Exacerbations in Subjects with Severe Chronic Obstructive Pulmonary Disease (COPD) Study Listed on
SCO40041 Completed A Randomized, Double-Blind, Parallel-Group Clinical Trial Evaluating the Effect of the fluticasone propionate/salmeterol Combination Product 250/50mcg twice daily via DISKUS® inhaler versus salmeterol 50mcg twice daily via DISKUS® inhaler on Bone Mineral Density in Subjects with Chronic Obstructive Pulmonary Disease (COPD) Study Listed on



For more information on this register please email

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party. is a database that provides summary protocol information for ongoing clinical trials. is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.